Denosumab and Slow-Jogging Aerobic Exercise in Aromatase Inhibitor-Associated Musculoskeletal Syndrome: A Case Series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41955552.
- Also identified by DOI 10.1097/PHM.0000000000002992.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As breast cancer incidence rises, aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) has become increasingly prevalent, yet treatment remains diverse and lack clearly defined therapeutic targets. We report three postmenopausal breast cancer patients (mean age: 64.6 y) who developed AIMSS after more than six months of AIs therapy. After receiving denosumab and participating in slow-jogging aerobic exercise aimed at improving bone mineral density and reducing the android-to-gynoid fat ratio, all three patients demonstrated marked improvements in pain scores (Visual Analog Scale, VAS), grip strength, and joint imaging after one year of follow-up. Beyond traditional anti-inflammatory medications and symptom-focused management, we propose viewing AIMSS as a metabolic condition induced by hormone suppression that leads to arthritis. The combination of denosumab and slow- jogging aerobic exercise may help alleviate symptoms and improve adherence to AIs therapy in patients with AIMSS.